How Targeted Therapy Is Changing The Treatment Of Advanced Cervical Cancer

For most of the twentieth century, the conversation about advanced cervical cancer was a short one. When the disease had spread beyond the cervix, or had returned after initial treatment, oncologists reached for chemotherapy. They tried different drugs, different pairings, different schedules. Tumours often shrank. Women often felt better for a while. But when researchers looked at how long patients actually lived, the answer barely moved, whichever combination they used.

That is a difficult thing to sit with, both for the woman receiving treatment and for the doctor offering it. It is also the reason the last decade matters. Since 2014, three separate classes of drug have shown, in large randomised trials, that they extend survival in this setting. None of them is a cure. All of them changed what an oncologist can honestly offer.

What “Advanced” Means In This Context

The word covers three overlapping situations, and the distinction matters because it shapes what treatment is trying to achieve.

Metastatic disease has spread to distant organs, commonly the lungs, liver, bones, or lymph nodes outside the pelvis. Recurrent disease has come back after treatment that was intended to cure. Persistent disease never fully cleared despite that treatment.

In all three, the goal of systemic therapy shifts. Surgery and chemoradiation aim for cure in earlier-stage disease. Once cancer is metastatic, recurrent, or persistent, treatment aims to control the disease, extend life, and preserve quality of life for as long as possible. Understanding that shift is part of understanding the numbers that follow.

The prognosis has historically been poor. Across published series, roughly one in five women with metastatic cervical cancer is alive at five years. The whole point of the research described below is to move that figure.

Why The Disease Resisted Chemotherapy For So Long

By the early 2000s, the standard first-line approach for advanced or recurrent cervical cancer treatment was cisplatin paired with paclitaxel. The pairing produced respectable response rates. Scans looked better. But median overall survival stayed stubbornly close to a year, and swapping one cytotoxic drug for another did not change it.

The reason is worth understanding, because it explains why the newer drugs work differently. Chemotherapy targets cells that divide rapidly. Cancer cells do divide rapidly, but so do the cells lining the gut, the hair follicles, and the bone marrow, which is why chemotherapy causes the side effects it does. More importantly, tumour cell populations are not uniform. Some cells divide slowly, evade the drug, and repopulate. Escalating the dose escalates the toxicity faster than it escalates the benefit.

To do better, researchers needed to attack something other than cell division.

Trial That Shifted The Standard

That something turned out to be the tumour’s blood supply.

A solid tumour cannot grow beyond roughly one to two millimetres on diffusion alone. To get larger, it must recruit its own vasculature. It does this by secreting vascular endothelial growth factor, or VEGF, a signalling protein that instructs nearby blood vessels to sprout new branches into the tumour mass. This process, angiogenesis, supplies the oxygen and nutrients that growth, local invasion, and metastasis all depend on.

Bevacizumab is a monoclonal antibody that binds circulating VEGF-A and prevents it from reaching receptors on the endothelial cells that line blood vessels. The signal never arrives. The new vessels do not form.

The Gynecologic Oncology Group tested whether this would translate into survival. GOG-240 enrolled 452 women with metastatic, persistent, or recurrent cervical carcinoma across 81 centres in the United States, Canada, and Spain, randomising them to chemotherapy alone or the same chemotherapy plus bevacizumab at 15 mg/kg.

The results, published in the New England Journal of Medicine in 2014, were the first meaningful movement in decades. Median overall survival rose from 13.3 months to 17.0 months, with a hazard ratio for death of 0.71. Response rates improved from 36% to 48%. A separate patient-reported outcomes analysis found the survival gain did not come at the cost of measurably worse quality of life.

Three point seven months is not a triumphant number, and it deserves to be stated plainly rather than dressed up. What made it significant was that it was the first time anything had moved the survival curve at all, and that the final analysis published in The Lancet in 2017 confirmed the benefit held with longer follow-up, with no rebound effect once the drug was stopped. The US Food and Drug Administration approved bevacizumab for this indication in August 2014.

What Treatment Actually Involves

Bevacizumab is given as an intravenous infusion in a hospital or day oncology unit, typically every three weeks alongside each chemotherapy cycle. The dose is calculated from body weight. The first infusion usually runs over about 90 minutes, and if it is well tolerated, later infusions are often shortened to around 30 minutes.

It is prescribed and supervised by a gynaecological oncologist. Two safety checks recur at almost every visit: blood pressure measurement and urine testing for protein. Both relate directly to how the drug works, since VEGF signalling also maintains normal blood vessels and the filtration barrier in the kidney.

Detailed drug information is published by the US National Cancer Institute and by Cancer Research UK, both of which are written for patients rather than clinicians and are worth reading before a first appointment.

Trade-Off, Stated Honestly

A common line in patient-facing writing is that targeted therapy avoids the side effects of chemotherapy. That is misleading. Targeted therapy has a different side effect profile, not an absent one, and in GOG-240 the differences were measurable.

Compared with chemotherapy alone, adding bevacizumab increased hypertension of grade 2 or higher from 2% to 25%, serious thromboembolic events from 1% to 8%, and gastrointestinal fistulas of grade 3 or higher from 0% to 3%.

The clinically important considerations are:

• Hypertension, the most common effect, usually manageable with antihypertensive medication.
• Proteinuria, protein leaking into the urine because of effects on the kidney’s filtration barrier, tracked by dipstick or laboratory testing.
• Impaired wound healing, which is why the drug must be paused around any planned surgery, generally with a margin of several weeks either side.
• Arterial thromboembolic events, including stroke and myocardial infarction, with higher risk in women who already have cardiovascular risk factors.
• Gastrointestinal perforation or fistula, uncommon but serious, and more likely in women who have had prior pelvic radiotherapy.
• Fatigue, nausea, and bone marrow suppression from the chemotherapy given alongside it.

None of this argues against the drug. It argues for the monitoring schedule, and for telling your oncology team about new symptoms early rather than waiting until the next scheduled visit.

Then Immunotherapy Arrived

Cervical cancer is caused by persistent infection with high-risk human papillomavirus. Because it is virally driven, researchers reasoned it might be visible to the immune system in a way other tumours are not, if the brakes the tumour applies could be released.

KEYNOTE-826 tested that idea in 617 women, adding the PD-1 inhibitor pembrolizumab to platinum-based chemotherapy, with or without bevacizumab. At the final analysis, after a median follow-up of 39.1 months, median overall survival among women whose tumours expressed PD-L1 with a combined positive score of 1 or higher was 28.6 months, against 16.5 months with chemotherapy alone. Among all participants regardless of PD-L1 status, it was 26.4 months versus 16.8 months.

Those are larger gains than bevacizumab produced on its own, and the benefit appeared whether or not bevacizumab was part of the regimen. Immune-mediated adverse events were more frequent, occurring in 34.5% of the pembrolizumab group compared with 16.5% of the control group. The FDA approved the combination in October 2021 for tumours with a combined positive score of 1 or higher.

For eligible women, chemotherapy plus pembrolizumab, with bevacizumab where appropriate, now represents the most effective first-line option available.

Beyond Bevacizumab: A Different Kind Of Targeting

The most recent development is not an antiangiogenic drug at all, and it addresses the situation that used to be bleakest: what to offer when first-line treatment stops working.

Tisotumab vedotin is an antibody-drug conjugate. An antibody directed at tissue factor, a protein often abundant on cervical tumour cells, is chemically linked to a potent cell-killing agent. The antibody delivers the payload to the tumour rather than distributing it throughout the body.

The innovaTV 301 trial randomised 502 women whose disease had progressed after prior therapy to receive either tisotumab vedotin or the investigator’s choice of single-agent chemotherapy. Median overall survival was 11.5 months versus 9.5 months, with a hazard ratio of 0.70. Objective responses occurred in 17.8% of patients versus 5.2%. It received full FDA approval in April 2024, having previously held accelerated approval.

Two months of median survival is a modest gain in absolute terms. In a setting where second-line options had almost nothing randomised evidence behind them, it is the first properly demonstrated one.

How To Read These Numbers

This is the part most articles skip, and it matters more than any individual statistic above.

Median survival is the point at which half a trial population had died, and half were still living. It is not a prediction for any individual. Some women in these trials lived considerably longer than the median; others considerably less. A median of 28.6 months does not mean a given patient has 28.6 months.

Trial populations are also selected. Participants in GOG-240 and KEYNOTE-826 had good performance status, adequate kidney, liver, and bone marrow function, and no non-healing wounds or active bleeding. Women who are frailer or who have other significant illnesses may not tolerate these regimens the way trial participants did.

And eligibility genuinely varies. PD-L1 status determines pembrolizumab eligibility in many settings. Prior pelvic radiotherapy raises fistula risk with bevacizumab. Cardiovascular history affects the thromboembolic calculation. This is why the treatment plan comes from an oncologist who has seen your scans, your pathology, and your history, and not from an article.

Part That Is Harder To Measure

Advanced cervical cancer is physically demanding and emotionally complicated in ways that treatment protocols do not capture.

Women facing this diagnosis commonly carry concerns about fertility, about sexual function after pelvic treatment, about the cost of prolonged systemic therapy, and about what an advanced diagnosis means for the people who depend on them. These are not side issues to be dealt with once the medical part is settled. They affect whether someone completes treatment at all.

Most cancer centres have psycho-oncology services, counsellors, or patient support coordinators, and many women do not learn this until well into treatment. Asking early costs nothing. So does asking the treating team directly about financial support, patient assistance programmes, and what the full course is likely to cost, rather than discovering it partway through.

Follow-Up And What To Report

Response is usually assessed with CT or PET-CT imaging after an agreed number of cycles. Between cycles, monitoring focuses on blood pressure, urine protein, kidney function, and blood counts.

Certain symptoms warrant contacting the oncology team the same day rather than waiting: unusual bleeding, severe abdominal pain, any change in vision or new neurological symptoms, signs that a wound is not healing, or new breathlessness or chest pain. Several of the serious complications associated with these regimens are far more manageable when caught early.

Context Worth Naming

There is an uncomfortable fact sitting underneath all of this progress: nearly every case of cervical cancer is preventable.

The disease is caused by persistent HPV infection, and both HPV vaccination and screening with a high-performance test are effective and cost-effective. The World Health Organization’s global elimination strategy sets targets for 2030 of vaccinating 90% of girls by age 15, screening 70% of women twice by age 45, and treating 90% of women found to have precancer or cancer. Modelling suggests achieving these targets could avert 74 million cases and 62 million deaths by 2120.

The gap between what is achievable and what is happening is starkest in the countries carrying most of the burden. In 2022, an estimated 662,301 women worldwide were diagnosed with cervical cancer, and 348,709 died of it. India alone accounted for 123,907 of those diagnoses and roughly 79,906 of the deaths, more than a fifth of the global total, against a national screening rate that published analyses place at around 2%. The IARC elimination planning data for India models how much of that could be prevented with rapid scale-up.

Better treatment for advanced disease is genuinely worth having. It is not a substitute for the vaccination and screening that would mean far fewer women ever needed it.

Closing Note

In a little over ten years, advanced cervical cancer has gone from a disease where no systemic treatment demonstrably extended life to one with three distinct drug classes that do: antiangiogenic therapy, checkpoint inhibition, and antibody-drug conjugates. The gains are measured in months rather than years, and it would be dishonest to describe them otherwise. But they are real, they are reproducible, they came from properly conducted randomised trials, and each one opened a door that further research is still walking through.

If you or someone close to you is facing this diagnosis, the most useful thing you can do is ask your oncologist which of these options applies to your specific situation, what the evidence behind it is, and what the trade-offs would be for you. Understanding what each part of a treatment plan is meant to do, and why it was chosen, is not a technicality. It is what makes a decision genuinely yours.

References

• Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. New England Journal of Medicine. 2014;370(8):734–743. doi:10.1056/NEJMoa1309748. GOG 240, ClinicalTrials.gov NCT00803062. https://www.nejm.org/doi/full/10.1056/NEJMoa1309748
• Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240). The Lancet. 2017;390(10103):1654–1663. doi:10.1016/S0140-6736(17)31607-0. https://pubmed.ncbi.nlm.nih.gov/28756902/
• Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. Journal of Clinical Oncology. 2023;41(36):5505–5511. doi:10.1200/JCO.23.00914. ClinicalTrials.gov NCT03635567. https://ascopubs.org/doi/abs/10.1200/JCO.23.00914
• Vergote I, Van Nieuwenhuysen E, Nakagawa S, Vidal L, Ray-Coquard I, Gennigens C, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. New England Journal of Medicine. 2024;391(1):44–55. doi:10.1056/NEJMoa2313811. innovaTV 301/ENGOT-cx12/GOG-3057, ClinicalTrials.gov NCT04697628. https://www.nejm.org/doi/full/10.1056/NEJMoa2313811
• World Health Organization. Cervical Cancer. WHO Fact Sheet. Geneva: World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer